In this presentation, I will present our ongoing work on our genomic characterization of primary and metastatic brain tumors.  We have identified novel drivers and potentially clinically actionable mutations in meningiomas, craniopharyngiomas and brain metastases. We have translated these findings to clinical trials, including novel national multicenter genomically-driven trials.

Short Bio

Originally from Vancouver, BC, Dr. Priscilla Brastianos completed her medical school and internal medicine residency at Johns Hopkins School of Medicine and fellowship training in hematology/oncology and neuro-oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. She is now director of the Central Nervous System Metastasis Center at Massachusetts General Hospital and leads a multi-R01-funded laboratory. Dr. Brastianos’ research focuses on understanding the genomic mechanisms that drive primary and metastatic brain tumors. She has lead studies which have identified novel therapeutic targets in brain tumors. She has more than 125 scientific publications and has translated her scientific findings to national multicenter trials. She also leads a multidisciplinary central nervous system metastasis clinic at Massachusetts General Hospital/Harvard Medical School. She has received a number of awards for her work including a ‘NextGen Star’ award by the American Association for Cancer Research, a Damon Runyon Clinical Investigator Award, a Breast Cancer Research Foundation Award, a Susan G. Komen Career Catalyst Award, and the American Brain Tumor Association Joel Gingras Award.

There is no recording of this seminar available.